DYN
Dyne Therapeutics (NASDAQ: DYN) fell around 10% in after-hours trading after announcing plans to raise $300...
Article Summary
HOLD- Dyne Therapeutics (NASDAQ: DYN) fell around 10% in after-hours trading after announcing plans to raise $300 million through a public stock offering, a day after the FDA accepted its application seeking approval for z-rostudirsen for Duchenne muscular dystrophy.
- Dyne Therapeutics also granted underwriters a 30-day option to buy up to an additional $45 million in shares, subject to market conditions, with all shares sold by Dyne.
- The FDA granted the application Priority Review and set a target decision date of January 21, 2027, with Dyne having said it expects a potential U.S. launch in early 2027 if approved.
- As of March 31, Dyne held $972.2 million in cash, cash equivalents, and marketable securities, with proceeds from the offering and $50 million debt draw expected to fund operations into the second quarter of 2028, with the company also starting two global late-stage trials and four preclinical candidates in its pipeline.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 15.4% | 25% | 50.0 ptsMeets Minimum (15.4%) - Passes screener |
| Target Price Upside ? | 65.0% | 20% | 100.0 ptsMassive Upside (65.0%) - Target: $39.33 vs Current: $23.83 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -4.7% | 15% | 20.0 ptsBarely a Dip (-4.7%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About DYN
- Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
- The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
- Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.